熊猫tv

专利出海交易爆发 中国创新药成为“全球合伙人”,专利出海交易爆发 中国创新药成为“全球合伙人”_我的网站

一 |     (Yonhap)South Korea’s business sentiment rose to its highest level in nearly four years in August, driven by improving confidence in the manufacturing sector led by semiconductors, increased passenger demand during the summer vacation season, and a recovery in the information and communications technology (ICT) sector.According to the Bank of Korea on Wednesday, the composite business sentiment index (CBSI) for all industries rose 1.1 points from July to 99.6 in August. It was the highest level since September 2022, when the index stood at 102, marking a second straight monthly increase after falling 1.2 points in June and rising 0.8 points in July.The CBSI is a measure of corporate sentiment calculated from five major indicators for manufacturing and four for non-manufacturing. A reading above the 2003-2025 average of 100 signals optimism, while a reading below 100 signals pessimism.The BOK noted that manufacturing, led by semiconductors, has driven the recovery in business sentiment since the downturn in late 2022, while nonmanufacturing also improved this month, pushing overall sentiment to a nearly four-year high.The manufacturing CBSI rose 0.6 point to 103.8 in August, extending its gains to five straight months and reaching its highest level since June 2022, when it was 107.1. It has stayed above its long-term average of 100 for four months after surpassing it in May at 100.8, its first reading above 100 in three years and nine months.Higher finished-product inventories, up 0.6 point, and improved financial conditions, up 0.4 point, drove the August gain.The CBSI for large companies fell 1.6 points to 103.7, ending a five-month rise, while the index for small and midsize enterprises rose 2.2 points to 99.8, its highest since June 2023, when it was 103.2. Sentiment among small and midsize enterprises has risen for two straight months since July.The CBSI for export-oriented companies rose 1 point to 108.5, its highest since May 2022, when it was 114. The index for domestic-oriented companies fell 0.6 point to 99.4.The BOK, however, called the declines at large and domestic-oriented companies temporary, saying sentiment has broadly improved across companies of all sizes and both export- and domestic-oriented businesses since the start of the year.The nonmanufacturing CBSI rose 1.5 points to 96.7, rebounding after two straight monthly declines from May’s 97.5. Higher sales, up 0.6 point, and improved financial conditions, up 0.5 point, led the gain.The BOK said nonmanufacturing sentiment improved more sharply as transportation and passenger demand increased during the summer vacation season and the broadcasting, film and services industries recovered.Among manufacturers, sentiment in electronics, video and telecommunications equipment improved on higher printed circuit board prices and the use of stockpiled inventories as operating rates were reduced during the vacation season.Food products also improved as the exchange rate lowered prices for imported ingredients and selling prices rose for products including processed meat.In nonmanufacturing, transportation and warehousing sentiment improved on higher ocean freight rates and increased passenger demand, while information and communications sentiment rose on better performance among video, broadcasting and IT service companies.The outlook for September also improved, with the all-industry CBSI forecast rising 3.1 points from August to 99.6. The manufacturing outlook rose 2 points to 102.5 and the nonmanufacturing outlook 3.9 points to 97.6.The Economic Sentiment Index (ESI), which combines the BSI and Consumer Sentiment Index (CSI), rose 1.5 points to 99.4 in August. Its seasonally adjusted cyclical component rose 0.4 points to 96.9, the highest since September 2022, when it was 97.9.The survey was conducted from August 10 to 18 among 3,524 companies nationwide, with 3,170 responding, including 1,770 manufacturers and 1,400 nonmanufacturers.。    　　央广网北京8月26日消息(记者夏青)据中央广播电视总台经济之声报道，国内创新药审批又有新进展。8月17日至23日，共有34款1类创新药首次在中国获批临床试验默示许可。还有一组更亮眼的数据：今年上半年，中国创新药对外授权共达成81笔合作，交易总额约1100亿美元，已经达到2025年全年总额的80%，再创历史同期新高。　　业内专家表示，这背后更重要的是中国创新药企角色的根本性转变。从过去的“原料供应商”，升级为与跨国药企平等对话、利益共享的“全球合伙人”。　　上半年科创板创新药企业绩亮眼　　创新药因研发难度大、附加值高，被誉为医药产业“皇冠上的明珠”。

二 | 2026年上半年，科创板创新药企交出了漂亮“成绩单”。

三 | 　　诺诚健华报告显示，上半年营收同比增长55.5%，达到11.4亿元，净利润2.4亿元，同比扭亏为盈。泽璟制药也交出上市以来首份盈利半年报，百济神州则交出史上最优半年度成绩单。　　“科创板创新药企业已经开始进入盈利兑现期。”苏商银行特约研究员武泽伟分析，“当前，创新药行业的商业化能力修复，海外权益合作持续落地，有效补充企业的运营现金流。

四 | 国内审评与支付机制不断优化，缩短新药的上市周期，拓宽产品收入边界。依托完整的产业链红利，国内的生物医药配套体系日趋成熟，研发服务企业持续承接海内外订单，充分分享全球研发投入回暖带来的业务增量。”　　中国创新药对外授权交易额迭创新高　　中国创新药获得全球市场的认可。2025年全年，中国药企的对外授权潜在交易总金额高达1356.55亿美元，是2024年的两倍多，一举登顶全球首位。今年上半年，中国创新药对外授权交易总额约1100亿美元，达到了去年全年总额的八成，再创历史新高。　　国家药监局药品注册管理司副司长蓝恭涛介绍，中国在研新药数量约占全球30%，位列全球第二。中国医药产业创新效率居世界前列。　　蓝恭涛说：“2025年我国批准的11个新靶点、新机制药品中，4个是国产创新药，占比不到一半。

五 | 今年上半年，我国批准的11个新靶点、新机制药品全都是自主研发的国产创新药。”　　中国药企正从“跟跑者”转变为“合作者”　　中国创新药实现了从“卖产品”到“卖技术”的跨越，中国创新药企业正在以“全球合作伙伴”的身份，与跨国药企联合开发、共享收益。　　武泽伟说：“未来，行业会逐步脱离同质化跟随研发，转向全新靶点与全新机制的源头创新。出海模式也从早期对外授权，过渡到自主完成海外申报与全球商业化运营。产业从产品出海升级为技术平台与研发体系的对外输出，整体国际竞争力稳步增强。”　　国家医保局近日发布《全民医疗保障“十五五”规划》，明确支持创新药纳入医保、推动商保创新药目录，释放强烈利好信号。　　中国医药创新促进会首席专家宋瑞霖说：“中国的创新药现在正处在一个历史性的崛起阶段，我们经历了从‘跟跑’到‘并跑’，现在我们正处于部分领域‘领跑’的阶段。大部分的跨国制药企业在未来的5年到10年都有一大批专利要到期，所以中国的创新药研究现在成为全球跨国制药企业争抢的目标。

Current article:http://www.roubutianquegumaigoubingdian.cyou/30f/rxcz.doc

Published on:01:19:04